Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The Eli Lilly deal will see the company launch a “real-world” study to understand how tirzepatide — the GLP-1 treatment behind its Zepbound and Mounjaro drugs — impacts weight loss ...

The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ...

Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity ... has said that Mounjaro (tirzepatide) can be used within the NHS for weight loss and weight maintenance ...

INDIANAPOLIS (AP) — Eli Lilly is pouring another ... there to make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. Those drugs have funneled fresh revenue ...